Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Clinical trial NCT04421560 · RECRUITING

Trial details

NCT number: NCT04421560
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma Recurrent Cancer Refractory Cancer Relapsed Cancer

Start date: 2020-08-01
Primary completion: 2026-12-05
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.